FDA Approves Nivolumab for Some Metastatic Colorectal Cancers

FDA has granted accelerated approval to the immunotherapy drug nivolumab (Opdivo®) for patients with metastatic colorectal cancer whose tumors have alterations that affect DNA repair.

Cancer Currents: An NCI Cancer Research Blog